Literature DB >> 17305413

Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety.

Nicholas Moore1.   

Abstract

Non-prescription (over-the-counter [OTC]) analgesics are used for the short-term treatment of acute painful conditions of mild to moderate intensity in everyday life. Well documented safety and efficacy, a rapid onset of action and a flexible daily dosing regimen are essential in this context. Film-coated, immediate-release, low-dose diclofenac potassium, developed for OTC use, offers a flexible daily dosing regimen with an initial dose of two tablets (2 x 12.5mg) followed by one or two tablets up to a maximum daily dose of six tablets (75 mg/day). The maximum plasma drug concentration is reached 30 minutes after administration, and the mean terminal half-life is 1-2 hours, allowing a 4- to 6-hour duration of activity, depending on the condition. Thirteen randomised, double-blind trials with both placebo and active controls have demonstrated the efficacy of diclofenac potassium 12.5mg tablets in conditions suitable for treatment with OTC medication, for example, acute lower back pain, headache, acute pain after dental extraction, symptoms of cold and influenza (including fever), and dysmenorrhoea. A single dose of diclofenac potassium 12.5mg is the lowest recommended effective dose. A two-tablet single dose of 25mg is at least as effective as ibuprofen 400mg. A flexible dosing regimen of an initial two tablets followed by one or two tablets up to a total daily dose of 75 mg is as effective as ibuprofen used in comparable fashion up to a total daily dose of 1200 mg. The incidence of adverse events in patients taking single or multiple doses of diclofenac potassium is similar to that of ibuprofen and placebo. In a safety study conducted to compare diclofenac potassium with ibuprofen for up to 3 months in patients with osteoarthritis of the knee, no differences in the pattern of adverse events were noted. There was no evidence of either hepatic injury or cardiovascular safety-related issues at any time during the study. Patients are generally capable of taking diclofenac potassium appropriately. A maximum OTC treatment duration of 5 days for pain and 3 days for fever is recommended.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305413     DOI: 10.2165/00044011-200727030-00002

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  103 in total

1.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

2.  The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.

Authors:  U Yasar; E Eliasson; C Forslund-Bergengren; G Tybring; M Gadd; F Sjöqvist; M L Dahl
Journal:  Eur J Clin Pharmacol       Date:  2001-12       Impact factor: 2.953

3.  Diclofenac potassium in the management of dental pain: a multicenter double-blind comparison with glafenine.

Authors:  W Boghdady; M Lotfy; E William
Journal:  Egypt Dent J       Date:  1993-07

4.  Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction.

Authors:  Lorenz M Fischer; Raymond G Schlienger; Christian M Matter; Hershel Jick; Christoph R Meier
Journal:  Pharmacotherapy       Date:  2005-04       Impact factor: 4.705

5.  The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs.

Authors:  G M Greig; D A Francis; J P Falgueyret; M Ouellet; M D Percival; P Roy; C Bayly; J A Mancini; G P O'Neill
Journal:  Mol Pharmacol       Date:  1997-11       Impact factor: 4.436

6.  The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man.

Authors:  V A John
Journal:  Rheumatol Rehabil       Date:  1979

7.  Relief of acute low back pain with diclofenac-K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo-controlled clinical trial.

Authors:  R L Dreiser; M Marty; E Ionescu; M Gold; J H Liu
Journal:  Int J Clin Pharmacol Ther       Date:  2003-09       Impact factor: 1.366

8.  Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans.

Authors:  T B Vree; M van den Biggelaar-Martea; C P Verwey-van Wissen; J B Vree; P J Guelen
Journal:  Biopharm Drug Dispos       Date:  1993-08       Impact factor: 1.627

9.  Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid.

Authors:  B Bannwarth; F Lapicque; F Pehourcq; P Gillet; T Schaeverbeke; C Laborde; J Dehais; A Gaucher; P Netter
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

10.  Pharmacokinetic studies on diclofenac sodium in young and old volunteers.

Authors:  J V Willis; M J Kendall
Journal:  Scand J Rheumatol Suppl       Date:  1978
View more
  11 in total

Review 1.  Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.

Authors:  Nicholas Moore
Journal:  Drug Saf       Date:  2020-04       Impact factor: 5.606

Review 2.  Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury.

Authors:  B H McCarberg; C E Argoff
Journal:  Int J Clin Pract       Date:  2010-10       Impact factor: 2.503

3.  Effects of plasticizers and surfactants on the film forming properties of hydroxypropyl methylcellulose for the coating of diclofenac sodium tablets.

Authors:  Amitava Roy; Amitava Ghosh; Supriya Datta; Sujit Das; P Mohanraj; Jyotirmoy Deb; M E Bhanoji Rao
Journal:  Saudi Pharm J       Date:  2009-08-07       Impact factor: 4.330

4.  Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells.

Authors:  Simona Bancos; Matthew P Bernard; David J Topham; Richard P Phipps
Journal:  Cell Immunol       Date:  2009-04-05       Impact factor: 4.868

Review 5.  Diclofenac epolamine (Flector) patch: evidence for topical activity.

Authors:  Birte Petersen; Stefano Rovati
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 6.  Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology.

Authors:  Roy Altman; Bill Bosch; Kay Brune; Paola Patrignani; Clarence Young
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

7.  Assessment of rescue opioid use in patients with post-bunionectomy pain treated with diclofenac potassium liquid-filled capsules.

Authors:  Joyce S Willens; Iwona Bucior; Shay Bujanover; Neel Mehta
Journal:  J Pain Res       Date:  2015-02-04       Impact factor: 3.133

8.  Efficacy, tolerability, and safety of an oral enzyme combination vs diclofenac in osteoarthritis of the knee: results of an individual patient-level pooled reanalysis of data from six randomized controlled trials.

Authors:  Michael A Ueberall; Gerhard Hh Mueller-Schwefe; Rainer Wigand; Ute Essner
Journal:  J Pain Res       Date:  2016-11-04       Impact factor: 3.133

9.  An investigation of the views and practices of Australian community pharmacists on pain and fever management and clinical guidelines.

Authors:  John Mishriky; Ieva Stupans; Vincent Chan
Journal:  Pharm Pract (Granada)       Date:  2019-06-11

10.  Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial.

Authors:  Alain Jacquet; Pierre-Olivier Girodet; Antoine Pariente; Karelle Forest; Laurent Mallet; Nicholas Moore
Journal:  Arthritis Res Ther       Date:  2009-12-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.